Vertex Pharmaceuticals (NASDAQ:VRTX) had its target price increased by Credit Suisse Group from $195.00 to $196.00 in a research note published on Tuesday. The brokerage currently has an outperform rating on the pharmaceutical company’s stock.

VRTX has been the topic of several other reports. Leerink Swann reaffirmed an outperform rating and set a $190.00 price target (up from $175.00) on shares of Vertex Pharmaceuticals in a research note on Thursday, February 1st. BMO Capital Markets raised their price target on shares of Vertex Pharmaceuticals from $184.00 to $191.00 and gave the stock a buy rating in a research note on Thursday, February 1st. Barclays raised their price target on shares of Vertex Pharmaceuticals from $180.00 to $200.00 and gave the stock an overweight rating in a research note on Thursday, February 1st. Jefferies Group reaffirmed a buy rating and set a $195.00 price target on shares of Vertex Pharmaceuticals in a research note on Thursday, February 1st. Finally, Royal Bank of Canada raised their price target on shares of Vertex Pharmaceuticals to $200.00 and gave the stock an outperform rating in a research note on Thursday, February 1st. Two analysts have rated the stock with a sell rating, three have given a hold rating and twenty-five have issued a buy rating to the stock. Vertex Pharmaceuticals currently has an average rating of Buy and a consensus target price of $183.11.

Shares of Vertex Pharmaceuticals (VRTX) opened at $154.14 on Tuesday. The company has a market cap of $38,980.00, a PE ratio of 79.05, a P/E/G ratio of 2.23 and a beta of 1.61. Vertex Pharmaceuticals has a 12 month low of $84.39 and a 12 month high of $174.96. The company has a quick ratio of 4.58, a current ratio of 4.79 and a debt-to-equity ratio of 0.01.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings data on Wednesday, January 31st. The pharmaceutical company reported $0.61 EPS for the quarter, beating the Zacks’ consensus estimate of $0.53 by $0.08. The firm had revenue of $651.63 million for the quarter, compared to analysts’ expectations of $592.49 million. Vertex Pharmaceuticals had a net margin of 10.59% and a return on equity of 11.02%. The firm’s revenue was up 42.1% on a year-over-year basis. During the same period in the prior year, the company earned $0.35 EPS. equities analysts anticipate that Vertex Pharmaceuticals will post 1.63 earnings per share for the current year.

Vertex Pharmaceuticals declared that its Board of Directors has authorized a stock buyback program on Wednesday, January 31st that authorizes the company to buyback $500.00 million in outstanding shares. This buyback authorization authorizes the pharmaceutical company to repurchase shares of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s board of directors believes its stock is undervalued.

In related news, CEO Jeffrey M. Leiden sold 125,000 shares of the firm’s stock in a transaction that occurred on Monday, December 11th. The shares were sold at an average price of $141.35, for a total value of $17,668,750.00. Following the transaction, the chief executive officer now owns 237,407 shares in the company, valued at $33,557,479.45. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Thomas Graney sold 777 shares of the firm’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $149.95, for a total transaction of $116,511.15. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 402,944 shares of company stock worth $62,121,632. Insiders own 1.80% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of VRTX. Advisory Services Network LLC raised its holdings in Vertex Pharmaceuticals by 337.6% in the fourth quarter. Advisory Services Network LLC now owns 792 shares of the pharmaceutical company’s stock valued at $119,000 after buying an additional 611 shares during the period. Smithfield Trust Co. purchased a new stake in shares of Vertex Pharmaceuticals during the third quarter valued at approximately $135,000. Whittier Trust Co. raised its stake in shares of Vertex Pharmaceuticals by 153.5% during the fourth quarter. Whittier Trust Co. now owns 991 shares of the pharmaceutical company’s stock valued at $149,000 after purchasing an additional 600 shares during the period. FNY Managed Accounts LLC purchased a new stake in shares of Vertex Pharmaceuticals during the third quarter valued at approximately $162,000. Finally, Baldwin Brothers Inc. MA purchased a new stake in shares of Vertex Pharmaceuticals during the fourth quarter valued at approximately $184,000. Hedge funds and other institutional investors own 92.84% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Credit Suisse Group Increases Vertex Pharmaceuticals (VRTX) Price Target to $196.00” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another website, it was stolen and republished in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2018/02/14/credit-suisse-group-increases-vertex-pharmaceuticals-vrtx-price-target-to-196-00.html.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Analyst Recommendations for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.